Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024

/in , , , ,

Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024

https://doi.org/10.1002/prp2.70030

 

2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

/in , , , , ,

View Poster:
2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

/in , ,

View Poster:
2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

/in , ,

View Poster:
2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

/in , , , , ,

View Poster:
2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024

/in ,

Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024

https://doi.org/10.1016/j.celrep.2024.114784

2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway

/in , , , , ,

View Poster:
2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway

Palmer et al; “Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase” J Med Chem, 2024

/in ,

Palmer et al; “Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase” J Med Chem, 2024

https://doi.org/10.1021/acs.jmedchem.4c00702

Gustavvson et al; “The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1” Science Advances, 2024

/in ,

Gustavvson et al; “The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1” Science Advances, 2024

https://www.science.org/doi/10.1126/sciadv.adk1296?

Ma et al; “Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor” J. Med. Chem. 2024

/in ,

Ma et al; “Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor” J. Med. Chem. 2024

https://doi.org/10.1021/acs.jmedchem.4c00572